Xintela AB (XINT) - Total Liabilities
Based on the latest financial reports, Xintela AB (XINT) has total liabilities worth Skr36.95 Million SEK (≈ $3.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xintela AB - Total Liabilities Trend (2013–2024)
This chart illustrates how Xintela AB's total liabilities have evolved over time, based on quarterly financial data. See XINT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Xintela AB Competitors by Total Liabilities
The table below lists competitors of Xintela AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
|
India | Rs1.64 Billion |
|
Texmo Pipes and Products Limited
NSE:TEXMOPIPES
|
India | Rs1.37 Billion |
|
Algorae Pharmaceuticals Ltd
AU:1AI
|
Australia | AU$111.25K |
|
Surana Solar Limited
NSE:SURANASOL
|
India | Rs98.95 Million |
|
Rougier S.A.
PA:ALRGR
|
France | €57.41 Million |
|
Tecnisa S.A
SA:TCSA3
|
Brazil | R$905.84 Million |
|
Form Bio Co. Ltd.
KQ:377220
|
Korea | ₩38.97 Billion |
|
MDJM Ltd
NASDAQ:UOKA
|
USA | $379.58K |
Liability Composition Analysis (2013–2024)
This chart breaks down Xintela AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Xintela AB (XINT) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.09 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xintela AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xintela AB (2013–2024)
The table below shows the annual total liabilities of Xintela AB from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr30.75 Million ≈ $3.31 Million |
+119.39% |
| 2023-12-31 | Skr14.02 Million ≈ $1.51 Million |
-25.21% |
| 2022-12-31 | Skr18.74 Million ≈ $2.02 Million |
-9.88% |
| 2021-12-31 | Skr20.80 Million ≈ $2.24 Million |
-0.53% |
| 2020-12-31 | Skr20.91 Million ≈ $2.25 Million |
+169.10% |
| 2019-12-31 | Skr7.77 Million ≈ $836.07K |
+62.91% |
| 2018-12-31 | Skr4.77 Million ≈ $513.22K |
-53.11% |
| 2017-12-31 | Skr10.17 Million ≈ $1.09 Million |
+254.85% |
| 2016-12-31 | Skr2.87 Million ≈ $308.43K |
-9.33% |
| 2015-12-31 | Skr3.16 Million ≈ $340.17K |
+231.24% |
| 2014-12-31 | Skr954.29K ≈ $102.70K |
-52.34% |
| 2013-12-31 | Skr2.00 Million ≈ $215.50K |
-- |
About Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more